One branch is the wholly-owned subsidiary Epichem, which provides services in synthetic and medicinal chemistry to the global drug discovery and pharmaceutical industries. It has projected sales of three to four million dollars this year, with expectations that the figure will grow substantially following significant expansion in the past twelve months.
The second branch involves drug repurposing, currently focused on Monepantel (MPL). PharmAust is working to establish the veterinary parasite medicine as an oncology treatment for dogs. At the same time, it is working to cross over into human cancer fighting applications.